Filtered By:
Condition: Thrombosis
Drug: Clopidogrel

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 536 results found since Jan 2013.

Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com
CONCLUSIONS: Long-term DAPT using cilostazol reduced the recurrence of ischemic stroke and prolonged the recurrence-free time in male patients, but not in female patients.PMID:36070920 | DOI:10.5551/jat.63660
Source: Journal of Atherosclerosis and Thrombosis - September 7, 2022 Category: Cardiology Authors: Haruhiko Hoshino Kazunori Toyoda Katsuhiro Omae Kaito Takahashi Shinichiro Uchiyama Kazumi Kimura Keiji Yamaguchi Kazuo Minematsu Hideki Origasa Takenori Yamaguchi CSPS.com Trial Investigators Source Type: research

Factors affecting physician decision-making regarding antiplatelet therapy in minor ischemic stroke
ConclusionsMany factors affect doctors' decisions regarding antiplatelet therapy, especially guidelines, age, admission SBP level, and hypertensive disease.
Source: Frontiers in Neurology - September 1, 2022 Category: Neurology Source Type: research

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
Conclusions: In critically-ill patients with COVID-19, full-dose anticoagulation, but not clopidogrel, reduced thrombotic complications with an increase in bleeding, driven primarily by transfusions in hemodynamically stable patients, and no apparent excess in mortality.PMID:36036760 | DOI:10.1161/CIRCULATIONAHA.122.061533
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Erin A Bohula David D Berg Mathew S Lopes Jean M Connors Iljal Babar Christopher F Barnett Sunit-Preet Chaudhry Amit Chopra Wilson Ginete Michael H Ieong Jason N Katz Edy Y Kim Julia F Kuder Emilio Mazza Dalton McLean Jarrod M Mosier Ari Moskowitz Sabina Source Type: research

O10 The necessity of monitoring platelet response and adjusting antiplatelet agents for endovascular treatment of unruptured intracranial aneurysms: a single-center, retrospective, cohort study
ConclusionActive monitoring and adjustment antiplatelet agents did not reduce ischemic complications in endovascular treatment; however, tended to reduce the ischemic complication, especially in flow diversion. Low-dose prasugrel may be feasible without increasing hemorrhage in the endovascular treatment of unruptured intracranial aneurysms.ReferencesLi W. Effect of Adjusted Antiplatelet Therapy on Preventing Ischemic Events after Stenting for Intracranial Aneurysms. Stroke. 2021 Dec;52(12):3815–3825. DOI: 10.1161/StrokeAHA.120.032989. EPUB 2021 SEP 20. PMID: 34538087.Hwang G. Standard vs Modified Antiplatelet Prepar...
Source: Journal of NeuroInterventional Surgery - August 29, 2022 Category: Neurosurgery Authors: Moon, E., Kwon, B., Song, Y., Lee, D., Park, J., Suh, D. Tags: 14th Congress of the European Society of Minimally Invasive Neurological Therapy 2022 Meeting Abstracts Source Type: research

CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD)
CONCLUSION: The aim of the GENPAD study is to evaluate the efficacy, safety, and cost-effectiveness of a genotype-guided antithrombotic treatment strategy compared to conventional clopidogrel treatment in PAD patients.PMID:35988587 | DOI:10.1016/j.ahj.2022.08.001
Source: Atherosclerosis - August 21, 2022 Category: Cardiology Authors: J Kranendonk L H Willems Rj van der Vijver-Coppen M Coenen E Adang R Donders C J Zeebregts Vhm Deneer Mmpj Reijnen C Kramers M C Warl é Source Type: research

Apixaban for Anticoagulation after Robotic Mitral Valve Repair
CONCLUSIONS: Anticoagulation with apixaban after minimally invasive robotic MVRep is safe and has similar rates of bleeding and thromboembolism compared to patients treated with warfarin.PMID:35973484 | DOI:10.1016/j.athoracsur.2022.07.045
Source: The Annals of Thoracic Surgery - August 16, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Piotr K Mazur Arman Arghami Shea A Macielak Scott D Nei Jason K Viehman Katherine S King Richard C Daly Juan A Crestanello Hartzell V Schaff Joseph A Dearani Source Type: research

Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs
AbstractPurposeP2Y12 receptor inhibitors are drugs that decrease the risk of stent thrombosis and lower the long-term risk of non-stent-related myocardial infarction and stroke. They inhibit the binding of adenosine diphosphate (ADP) to the P2Y12 receptor and effectively reduce platelet reactivity. However, considerable variability in the pharmacodynamics response contributes to a failure of antiplatelet therapy; this phenomenon is especially notorious for older drugs, such as clopidogrel. Some genetic polymorphisms associated with these drugs ’ metabolic pathway, especially in the CYP2C19 gene, can significantly decreas...
Source: Cardiovascular Drugs and Therapy - August 9, 2022 Category: Cardiology Source Type: research

Efficacy and Safety of De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Meta-Analysis of Randomized Clinical Trials
Abstract: Considering that there is no definite conclusion on the efficacy and safety of switching from potent P2Y12 inhibitors to clopidogrel, we conducted a systematic review and meta-analysis of patients with acute coronary syndromes undergoing percutaneous coronary intervention and compared the efficacy and safety of de-escalation or not of antiplatelet therapy. The relevant randomized controlled trials were included by searching several databases. Net adverse clinical events were identified as the composite end point, which was defined as a composite of cardiovascular death, myocardial infarction, revascularizatio...
Source: Journal of Cardiovascular Pharmacology - August 1, 2022 Category: Cardiology Tags: Original Article Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

E-187 Pipeline embolization stent for treatment of giant supraclinoid aneurysms: a case series
ConclusionThe Pipeline embolization device is a novel technique that can be utilized for treatment of giant cerebrovascular aneurysms with emerging evidence of immediate and long-term success. Further patient enrollment and clinical trials will be required to assess its efficacy in comparison to other endovascular and surgical approaches for the treatment of giant aneurysms.Disclosures M. Fana: None. O. Alsrouji: None. M. Rehman: None.
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Fana, M., Alsrouji, O., Rehman, M. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research

O-052 The pennsylvania post-market multicenter experience with flow re-direction endoluminal device (FRED)
ConclusionThe results of the early post-market experience with the FRED device show reasonable safety and adequate aneurysmal occlusion rates comparable to other flow diverters. However, more extensive multicenter studies with more extended follow-up data are needed to assess the long-term safety and durability of the device.Abstract O-052 Table 1Baseline descriptive statistics Number of patients n=61 Gender Male 11 (18%) Female 50 (82%) Age (Years: median; IQR) 58 (51 – 68) Multiple Intracranial Aneurysms 21 (34.4%) Family history of aneurysms 9 (14.8%) Smoking History Never smokers 26 (42.6%) Past smokers 13 (21.3...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Salem, M., Kvint, S., Hendrix, P., Al Saiegh, F., Gajjar, A., Goren, O., Gross, B., Jabbour, P., Lang, M., Schirmer, C., Tjoumakaris, S., Griessenauer, C., Burkhardt, J. Tags: SNIS 19th annual meeting oral abstracts Source Type: research